ERC1671
Phase 2Small molecule
ERC1671 is one of 90 small molecule programs targeting Malignant Glioma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
89
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
292 competitors in Glioblastoma Multiforme
#DrugCompanyPhaseTrials
1Bicnu
MMelissa K Accordino
Phase 3
Aralen
SanofiPhase 3
Arava
SanofiPhase 3
Ceenu
AAzurity Pharmaceuticals
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Veliparib
AbbViePhase 3
Enzastaurin
Eli LillyPhase 3
Theraplaza
BBiotech Pharmaceutical Co., Ltd.
Phase 3
Afinitor
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ERC1671. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details